Convexia
AI-powered drug discovery 10x faster
Convexia is an AI-driven biotech platform focused on accelerating pharmaceutical drug discovery and development. It uses modular agents and over 50 computational models to identify and evaluate drug candidates, claiming to operate 10x faster and 20x leaner than incumbents.
Source: HealthTechAlpha
HealthTechAlpha provided this information. To learn more and get deep data on all digital health companies, please visit them here.
Visit HealthTechAlpha →How We Help
Problem Statement
Convexia addresses the limitations of traditional, manual diligence processes in drug discovery, which often lead to promising drug candidates being overlooked, shelved, or abandoned due to their slow and costly nature.
Core Technology
Convexia employs an AI-driven biotech platform featuring modular agents and over 50 custom-tuned computational models. These models evaluate drug candidates across domains like binding, ADME, toxicity, and immunogenicity, accelerating discovery and development.
Key Differentiators
Operates 10x faster than incumbents; Operates 20x leaner than incumbents; Operates without wet lab infrastructure, partnering with Contract Research Organizations (CROs); Includes human review layer with domain experts and Key Opinion Leaders (KOLs) validating AI findings
Clinical Focus
Drug Discovery; Drug Development; Clinical Trial Simulation
Company Info
- Business Model
- B2B SaaS
- Founded
- 2025
- Total Funding
- 500,000
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
In-silico computational biology models (ESM-3, AlphaFold), IND-enabling studies via CRO partnerships, clinical trial simulations, Phase 1 pathway planning, expert review by domain scientists
MedStartr Index Score
?What do you think of Convexia?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.